CRISPR Therapeutics
CRSP
396 hedge funds and large institutions have $2.2B invested in CRISPR Therapeutics in 2025 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 122 increasing their positions, 102 reducing their positions, and 60 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
27% more call options, than puts
Call options by funds: $96.3M | Put options by funds: $75.6M
20% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 102
0.25% less ownership
Funds ownership: 75.64% → 75.39% (-0.25%)
8% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 60
2% less funds holding
Funds holding: 405 → 396 (-9)
13% less capital invested
Capital invested by funds: $2.54B → $2.2B (-$339M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$53.5M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$50.5M |
| 3 |
Two Sigma Investments
New York
|
+$37.4M |
| 4 |
Morgan Stanley
New York
|
+$34.1M |
| 5 |
Two Sigma Advisers
New York
|
+$30.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$113M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$34.4M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$27.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$26.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$12M |
CRSP Hedge Fund Activity: Q1 2025 in Review
396 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2025, worth a combined $2.2B — down 13% from $2.54B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of CRSP and 55 opened new positions — a net loss of 5 holders — while 102 trimmed existing stakes and 122 added.
The largest buyer was UBS AM, adding an estimated $53.5M. The largest seller was Capital International Investors, cutting an estimated $113M.
- 396 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2025, down from 405 in Q4 2024.
- Funds reported $2.2B of CRISPR Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
- 55 funds opened new CRISPR Therapeutics positions in Q1 2025 and 60 closed out, a net change of -5 holders.
- The largest CRISPR Therapeutics buyer in Q1 2025 was UBS AM, an estimated $53.5M added.
- The largest CRISPR Therapeutics seller in Q1 2025 was Capital International Investors, an estimated $113M sold.
Based on aggregated 13F filings for Q1 2025.